Indian Pharmaceutical Market (IPM) improved during the month of November 2017 due to positive growth in volumes. According to AIOCD Pharmasofttech AWACS Pvt. Ltd, IPM has clocked growth of 8.1 per cent to Rs.10,291 crore. However, due to GST implementation, the growth in April-November for the industry remained at 4.6 per cent.

The GDs volumes increased by 6.5 per cent, but prices declined by 1.5 per cent which impacted the growth. The volumes have posted a positive growth however price component put pressure. MNCs grew by 4.4 per cent for Nov-17, while Indian companies moved faster at 9 per cent. The NLEM 2013 containing molecules market showed growth at 4.2 per cent whereas the non NLEM market grew at 9 per cent resulting in an overall growth of 8.1 per cent for the month of Nov 2017.

Anti-infectives registered growth of 7.9 per cent and dermatology achieved double digit growth of 11.9 per cent. Gastro intestinal has shown a positive turnaround this month and moved up by 9 per cent, while Vitamins post a positive growth of 6.8 per cent. However, major chronic therapy like anti-diabetic has slowed down by 6 per cent. Cardio segment has posted single digit growth of 4.4 per cent and CNS achieved growth of 7.6 per cent.

During April-October 2017, derma and anti-diabetics posted double digit growth of 11.6 per cent and 12.8 per cent respectively.

FDC related market showed growth of 16.5 per cent while the non FDC market showed a growth of 9.1 per cent while the single molecules grew at 6.9 per cent for the month Nov 17. Price component of GD for the FDCs was 0.4 per cent, other GDs in terms of volumes are at 15.5 per cent while new products are growing at 0.6 per cent. The Non FDC component growth drivers are volumes at 6.7 per cent, prices lower at 0.7 per cent while new products are growing at 3 per cent. The single molecules are driven by volumes at 6.5 per cent however the prices are pulling down by 2.3 per cent while new products are growing at 3 per cent.

FDCs mentioned here are those categories which got affected due to the FDC regulation which lead to a ban of several combinations leading to legal action by some companies. NON FDC are combination outside the purview of the FDC regulation.

Amongst the top 10 corporate, Mankind has the highest growth at 27.6 per cent followed by Alkem at 13.9 per cent and Lupin at 12.5 per cent. 43 corporate achieved positive growth amongst top 50, which could be a sign of revival. Amongst the top 50 corporate Natco has the highest growth of 35.9 per cent followed by Mankind growing at 27.6 per cent and Himalaya growing at 22.9 per cent.

Abbott HC improved by 13.1 per cent and Abbott India by 14.1 per cent both are growing at double digit growth for Nov-17. Sun portfolio has shown slight slowdown at 5.8 per cent, while Ranbaxy has registered a growth of 7.6 per cent. Total 26 companies launched in last 36 months. And one company cross Rs.10 crore mark in revenue.

Amongst the top 60 MNCs, Allergan was the fastest growing at 22.1 per cent followed by Eli Lilly growing at 12.7 per cent and Novartis which grew at 11.5 per cent for Nov -17.

From therapy perspective 18 therapies are showing a positive growth for the month of Nov -17. Respiratory market posted a double growth of 13.8 per cent, Gastro intestinal and pain and analgesic market showed growth of 9 per cent. Anti-diabetic market slowed down at 6 per cent & cardiac at 4.4 per cent, Neuro/CNS showed a growth of 7.6 per cent for month of Nov-17 amongst the chronic care categories. Anti-malarials degrew at -4.5 per cent & VMS market is growing at 6.8 per cent.

From regional perspective 29 regions have posted positive growth for month of Nov-17. Jharkhand market grew the highest at 21.3 per cent followed by UP East at 17.6 per cent & North Karnataka at 16.1per cent.

Amoxycillin+clavulanic acid market is showing a recovery at 12.02 per cent monthly growth in Nov -17. Glimepiride +metformin market is stagnant at 0.17 per cent. Glimepiride +metformin was pegged at Rs.171.7 crore & amoxycillin +clavulanic acid market pegged at Rs.175.6 crore in Nov-17. Azilsartan plain market is now valued at Rs.51.44 crore on Mat basis. Sofosbuvir and its combination market has reached Rs.566 crore on Mat basis. The luliconazole market is worth Rs.219.2 crore on MAT basis. While tenegliptin and its combinations are pegged at Rs.569.3 crore. The market of paracetamol plain is growing at 8.53 per cent on monthly basis, plain atorvastatin is declining at -7.63 per cent. Probiotic microbes is showing a double digit growth of 20.07 per cent, pantoprazole plain has posted a double digit growth of 11.83 per cent, montelukast + levocetrizine is growing close to 13.08 per cent, voglibose + metformin + glimepiride  has posted a double digit growth of 14.65 per cent, plain azithromycin is showing monthly growth of 11.67 per cent.

Mixtard leads the pack with Rs.41 crore followed by Glycomet GP at Rs.35 crore, Spasmoproxyvon plus at Rs.38 crore, Lantus at Rs.31 crore & Galvus Met at Rs.42 crore and Liv 52 at Rs.21 crore and Janumet at Rs.30 crore for Nov-17. Few brands who have gained ranks on MAT basis include Novomix (+4), Cilacar (+28), Udiliv (+15), Ultracet (+9), Duolin, (+28), Gluconorm G (+10), Telma H (+7), Allegra (+18), Synflorix (+14), Gemer (+13), Ecosprin AV (+18), Duphaston (+15),Pan D (+10), Istamet (+6).

Azilsartan is a recently launched molecule now valued at Rs.51.44crore there are 43 brands already launched. On MAT basis with Zilarbi (Emcure) leading followed by Aztric (Intas) and Abel (Lupin). Luliconazole segment is worth Rs.219.2 crore on MAT basis there are already 36 brands in the foray. Benidipine molecule and its combinations is now valued at Rs.14.3 crore on MAT basis with Inzit (Eris) leading followed by Benitowa (Akumentis) and Benipack (Koye). Acotiamide molecule is now valued at Rs.41.7 crore on MAT basis with Acogut (Lupin) is leading followed by Actapro (Sun) & Acotrust (DRL). Dulaglutide launched under the brand nnme Trulicity by Eli Lilly is now valued at Rs.18 crore.

Within the anti-diabetic category there are 4 brands launched in the month of Nov -17 and that in VMS category there have been 4 brands launched. Within cardiac there have been 4 brands launched in Nov-17 and in derma there were 11 brands launched. Within gastro 7 new brands were launched in Nov -17.